Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage
Information source: Wyeth
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Peptic Ulcer Hemorrhage
Intervention: Pantoprazole (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: Wyeth Official(s) and/or principal investigator(s):
Medical Monitor, MD, Study Director, Affiliation: Wyeth
Summary
The purpose of this study is to evaluate the efficacy and safety of intravenous pantoprazole
in the prevention of rebleeding in patients with bleeding peptic ulcer disease after
successful endoscopic hemostatic therapy.
Clinical Details
Official title: An Efficacy and Safety Study of Intravenous Pantoprazole in the Prevention of Recurrent Peptic Ulcer Bleeding After Successful Hemostasis
Study design: Prevention, Safety/Efficacy Study
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients must be men or non-pregnant women at least 18 years of age
- Patients who present with a gastric or duodenal ulcer
Exclusion Criteria:
- Patients with ulcer appearance of clean base (non-oozing, non-spurting) or flat
pigmented spot; adherent clots not removed by irrigation
- Patients presenting with active bleeding and/or NBVV at 2 or more separate sites
- Patients with any severe concomitant diseases, eg, end stage liver or renal disease,
or unstable cardiovascular, pulmonary, renal, hepatic, or gastrointestinal diseases
Locations and Contacts
Additional Information
Last updated: May 18, 2006
|
